The APMAP Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product provides a heterogeneous gene-disrupted model for studying the adipocyte plasma membrane-associated protein (APMAP) in lung cancer biology. The pooled knockout cells retain the inherent diversity of a polyclonal population following CRISPR/Cas9-mediated gene disruption, preserving physiological variability while enabling robust functional analyses without clonal selection artifacts.
The A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a widely used in vitro model of human lung adenocarcinoma. These adherent epithelial cells are characterized by their expression of wild-type p53 and KRAS mutations, and are commonly employed to investigate tumor cell signaling, drug response, and metastatic behavior. The A-549 background is particularly relevant for studying the intersection of metabolic regulation and cancer, as these cells exhibit sensitivity to insulin and other metabolic hormones, making them suitable for modeling obesity- and diabetes-related cancer mechanisms.
APMAP encodes a plasma membrane protein with hyaluronidase-like activity that modulates hyaluronan degradation, influencing extracellular matrix (ECM) remodeling and cell adhesion. It is transcriptionally regulated by PPAR?? and insulin, and its expression is further modulated by TNF?? and IL-6. APMAP interacts directly with CD44 and hyaluronan, and forms complexes with ECM proteins and ADAMTS proteases. Downstream, APMAP-mediated hyaluronan catabolism generates bioactive fragments that potentiate CD44 signaling, promoting MMP expression and altered cell adhesion. This network includes hyaluronan-binding proteins RHAMM, hyaluronidases HYAL1/2, and hyaluronan synthases HAS1-3.
Knockout of APMAP in A-549 cells disrupts hyaluronan homeostasis, thus perturbing ECM integrity and CD44-mediated signal transduction. This is predicted to impair cell migration and invasion, processes fundamental to lung adenocarcinoma metastasis. Moreover, given APMAP’s role in insulin sensitivity and adipocyte differentiation, its loss may alter metabolic responses, including glucose uptake and lactate production, thereby linking energy metabolism to tumor progression. Consequently, this knockout model provides a powerful tool for dissecting how hyaluronan metabolism influences lung cancer cell behavior and the tumor microenvironment.
Researchers can employ these polyclonal knockout cells in assays such as hyaluronan degradation, western blotting for APMAP and CD44, RT-qPCR, immunofluorescence, scratch migration, transwell invasion, flow cytometry for CD44, and metabolic profiling (glucose uptake, lactate production). Applications include studying lung cancer metastasis, drug screening for hyaluronidase inhibitors, and analyzing ECM remodeling. For additional information or technical support, please contact Ascent Research.
